The recent clinical reports demonstrated that the CD19 CAR-T cell therapy had made remarkable progress in achieving a complete remission (CR) rate of 50% in R/R diffuse large B cell lymphoma (DLBCL) patients (1, 2). Here, CD19 is linked to diffuse large B-cell lymphoma.